CZ298027B6 - Process for preparing epothilone-N-oxides and N-oxides of epothilones per se - Google Patents

Process for preparing epothilone-N-oxides and N-oxides of epothilones per se Download PDF

Info

Publication number
CZ298027B6
CZ298027B6 CZ0286599A CZ286599A CZ298027B6 CZ 298027 B6 CZ298027 B6 CZ 298027B6 CZ 0286599 A CZ0286599 A CZ 0286599A CZ 286599 A CZ286599 A CZ 286599A CZ 298027 B6 CZ298027 B6 CZ 298027B6
Authority
CZ
Czechia
Prior art keywords
epothilone
oxides
oxide
epothilones
per
Prior art date
Application number
CZ0286599A
Other languages
Czech (cs)
Other versions
CZ286599A3 (en
Inventor
Hoefle@Gerhard
Sefkow@Michael
Original Assignee
Gesellschaft Fuer Biotechnologische Forschung Mbh(Gbf)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gesellschaft Fuer Biotechnologische Forschung Mbh(Gbf) filed Critical Gesellschaft Fuer Biotechnologische Forschung Mbh(Gbf)
Publication of CZ286599A3 publication Critical patent/CZ286599A3/en
Publication of CZ298027B6 publication Critical patent/CZ298027B6/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
  • Silicon Polymers (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Epoxy Compounds (AREA)

Abstract

The present invention relates to side chain-modified epothilones

Description

Způsob přípravy epothilon-N-oxidů a N-oxidy epothilonůProcess for the preparation of epothilone N-oxides and epothilone N-oxides

Oblast technikyTechnical field

Epothiolony A a B jsou známé; srovnej například DE 4 138 042, WO 93 10121 a WO 97 19086. Jmenovaný stav techniky je navrhuje jako terapeutické prostředky.Epothiolones A and B are known; cf., for example, DE 4,138,042, WO 93,10121 and WO 97,19086.

Dosavadní stav technikyBACKGROUND OF THE INVENTION

V PNAS USA 95 (1998) 1369 - 1374 jsou epothilony označovány jako užitečné terapeutické prostředky. V důsledku jejich terapeutických efektů se podle Angew. Chem. Int. Ed. 36 (1997) 2097 - 2103 bude dokonce opatřovat obsáhlá knihovna sloučenin tohoto druhu (extensive library of compounds).In PNAS USA 95 (1998) 1369 - 1374, epothilones are referred to as useful therapeutic agents. Due to their therapeutic effects, according to Angew. Chem. Int. Ed. 36 (1997) 2097-2103 will even provide an extensive library of compounds of this kind.

Podstata vynálezuSUMMARY OF THE INVENTION

Vynález se týká způsobu přípravy epothilon-N-oxidů, při němž se chráněný nebo nechráněný epothilon A nebo B o sobě známým způsobem převede na N-oxid.The present invention relates to a process for the preparation of epothilone N-oxides, wherein the protected or unprotected epothilone A or B is converted to the N-oxide in a manner known per se.

Tento postup podle vynálezu je s výhodou charakterizován tím že se N-oxidace provádí peroxykyselinou nebo dioxiranem.The process according to the invention is preferably characterized in that the N-oxidation is carried out with peroxyacid or dioxiran.

Předmětem vynálezu je rovněž epothilon-N-oxid (epothilon A-N-oxid) vzorceThe invention also provides an epothilone N-oxide (epothilone A-N-oxide) of the formula

r1, r2 = h, z = o; r = hr 1 , r 2 = h, z = o; r = h

Dále je předmětem vynálezu epothilon-N-oxid (epothilon B-N-oxid) vzorce:The present invention further provides an epothilone N-oxide (epothilone B-N-oxide) of the formula:

r1,r2 = h, z = o; r = ch3 r 1 , r 2 = h, z = o; r = ch 3

-1 CZ 298027 B6-1 CZ 298027 B6

Příklady provedení vynálezuDETAILED DESCRIPTION OF THE INVENTION

Příklad 1Example 1

Epothilon A-N-oxidEpothilone A-N-oxide

Ke 100 mg epothilonu A v 1 ml dichlormetanu bylo přidáno 100 mg 70% kyseliny w-chlorperoxybenzoové v 0,5 ml dichlorethanu. Po 6 hodinách míchání při teplotě místnosti bylo zředěno dichlormethanem a postupně vytřepáváno roztokem siřičitanu sodného a roztokem bikarbonátu sodného k odstranění přebytečné peroxykyseliny. Rozpouštědlo bylo odpařeno ve vakuu a zbytek byl rozdělen preparativní HPLC na sloupci Nucleosilu RP-18 (250 x 20 mm, mobilní fáze methanol/voda 60:40). Výtěžek 60 mg bezbarvého oleje.To 100 mg of epothilone A in 1 mL of dichloromethane was added 100 mg of 70% n-chloroperoxybenzoic acid in 0.5 mL of dichloroethane. After stirring at room temperature for 6 hours, it was diluted with dichloromethane and shaken successively with sodium sulfite solution and sodium bicarbonate solution to remove excess peroxyacid. The solvent was evaporated in vacuo and the residue was separated by preparative HPLC on a Nucleosil RP-18 column (250 x 20 mm, methanol / water 60:40 mobile phase). Yield: 60 mg colorless oil.

Rf= 0,60 (silikagel DC Alufolie, mobilní fáze dichlormethan/methanol 1:1);R f = 0.60 (silica DC Alufolie, mobile phase dichloromethane / methanol 1: 1);

ESI-MS (negativní ionty) m/z 510;ESI-MS (negative ions) m / z 510;

UV (methanol): Zmax = 240 nm;UV (methanol): λ max = 240 nm;

13C-NMR (CDC13): C-l 70,5, C-2 39,9, C-3 70,8, C^l 55,1, C-5 221,4, C-6 40,9, C-7 72,9, C8 37,6, C-9 31,8, C-10 22,8, C-l 1 28,0, C-12 58,0, C-13 55,8, C-14 32,2, C-15 75,5, C-16 144,5, C-17 111,4, C-18 143, 4, C-19 110,3, C-20 145,6, C-21 13,5, C-22 15,4, C-23 23,3, C24 12,0, C-25 16,5, C-27 18,2 ppm. 13 C-NMR (CDC1 3): C 70.5, C-2 39.9 C-3 70.8, C-L 55.1, C-5 221.4, C-6 40.9, C -7 72.9, C8 37.6, C-9 31.8, C-10 22.8, Cl-28.0, C-12 58.0, C-13 55.8, C-14 32, 2, C-15 75.5, C-16 144.5, C-17 111.4, C-18 143.4, C-19 110.3, C-20 145.6, C-21 13.5 C-22 15.4, C-23 23.3, C24 12.0, C-25 16.5, C-27 18.2 ppm.

Příklady syntézExamples of syntheses

Epothilon A-N-oxid: R1, R2 = H, Z = O', R = HEpothilone AN-oxide: R 1, R 2 = H, Z = O ', R = H

Epothilon B-N-oxid: R1, R2 = H, Z = O', R = CH3 Epothilone BN-oxide: R 1 , R 2 = H, Z = O ', R = CH 3

Claims (4)

1. Způsob přípravy epothilon-N-oxidů, vyznačený tím, že se 3,7-chráněný nebo nechráněný epothilon A nebo B o sobě známým způsobem převede na N-oxid.Process for the preparation of epothilone-N-oxides, characterized in that the 3,7-protected or unprotected epothilone A or B is converted into the N-oxide in a known manner. 2. Způsob podle nároku 1,vyznačený tím, že se N-oxidace provádí peroxykyselinou nebo dioxiranem.Process according to claim 1, characterized in that the N-oxidation is carried out with peroxyacid or dioxiran. 3. Epothilon-N-oxid (epothilon A-N-oxid) vzorce:3. Epothilone N-oxide (epothilone A-N-oxide) of the formula: kde R1, R2 = H, Z = O ; R = Hwherein R 1 , R 2 = H, Z = O; R = H 4. Epothilon-N-oxid (epothilon B-N-oxid) vzorce:4. Epothilone N-oxide (epothilone B-N-oxide) of the formula: kde R1, R2 = H, Z = O“, R = CH3 where R 1 , R 2 = H, Z = O ", R = CH 3
CZ0286599A 1997-02-25 1998-02-25 Process for preparing epothilone-N-oxides and N-oxides of epothilones per se CZ298027B6 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19707505 1997-02-25
PCT/EP1998/001060 WO1998038192A1 (en) 1997-02-25 1998-02-25 Epothilones with a modified side chain

Publications (2)

Publication Number Publication Date
CZ286599A3 CZ286599A3 (en) 2000-03-15
CZ298027B6 true CZ298027B6 (en) 2007-05-30

Family

ID=7821415

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ0286599A CZ298027B6 (en) 1997-02-25 1998-02-25 Process for preparing epothilone-N-oxides and N-oxides of epothilones per se

Country Status (25)

Country Link
US (1) US6359140B1 (en)
EP (2) EP1201666A3 (en)
JP (1) JP2001513098A (en)
KR (1) KR100494179B1 (en)
CN (2) CN1128803C (en)
AR (1) AR011878A1 (en)
AT (1) ATE221888T1 (en)
AU (1) AU736062B2 (en)
BR (1) BR9807742B1 (en)
CA (1) CA2281105A1 (en)
CZ (1) CZ298027B6 (en)
DE (2) DE59805110D1 (en)
DK (1) DK0975638T3 (en)
ES (1) ES2183338T3 (en)
HK (1) HK1023774A1 (en)
HU (1) HU228851B1 (en)
IL (1) IL131343A (en)
NO (1) NO327211B1 (en)
NZ (1) NZ337195A (en)
PL (1) PL190422B1 (en)
PT (1) PT975638E (en)
RU (1) RU2201932C2 (en)
TW (1) TW480263B (en)
WO (1) WO1998038192A1 (en)
ZA (1) ZA981575B (en)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59609305D1 (en) 1995-11-17 2002-07-11 Biotechnolog Forschung Gmbh Epothilone derivatives and their production
PT941227E (en) * 1996-11-18 2004-08-31 Biotechnolog Forschung Mbh Gbf EPOTHILONE AND ITS PREPARATION AND ITS USE AS A CITOSTATIC AGENT OR AS A PHYTOSANITARY PROTECTION AGENT
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
EP0977563B1 (en) * 1996-12-03 2005-10-12 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US20050043376A1 (en) * 1996-12-03 2005-02-24 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6867305B2 (en) 1996-12-03 2005-03-15 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6660758B1 (en) 1996-12-13 2003-12-09 The Scripps Research Institute Epothilone analogs
US6380394B1 (en) 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
EP1201666A3 (en) * 1997-02-25 2003-03-05 Gesellschaft für biotechnologische Forschung mbH (GBF) Epothilones with a modified side chain
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
US6320045B1 (en) 1997-12-04 2001-11-20 Bristol-Myers Squibb Company Process for the reduction of oxiranyl epothilones to olefinic epothilones
US6683100B2 (en) 1999-01-19 2004-01-27 Novartis Ag Organic compounds
US6399638B1 (en) 1998-04-21 2002-06-04 Bristol-Myers Squibb Company 12,13-modified epothilone derivatives
US6498257B1 (en) 1998-04-21 2002-12-24 Bristol-Myers Squibb Company 2,3-olefinic epothilone derivatives
DE19826988A1 (en) * 1998-06-18 1999-12-23 Biotechnolog Forschung Gmbh Epothilone minor components
ES2175575T3 (en) * 1998-08-05 2002-11-16 Biotechnolog Forschung Gmbh PHARMACEUTICAL AGENTS CONTAINING EPOTILONE N-OXIDE A AND / OR N-OXIDODE EPOTILONE B.
US6780620B1 (en) 1998-12-23 2004-08-24 Bristol-Myers Squibb Company Microbial transformation method for the preparation of an epothilone
US6596875B2 (en) 2000-02-07 2003-07-22 James David White Method for synthesizing epothilones and epothilone analogs
ES2209831T3 (en) 1999-02-22 2004-07-01 Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) MODIFIED EPOTILONES IN C-21.
DE19907588A1 (en) * 1999-02-22 2000-08-24 Biotechnolog Forschung Gmbh New C-21 modified epothilone derivatives useful for treating e.g. cancer and other proliferative diseases and inhibiting angiogenesis and inducing apoptosis
US20020058286A1 (en) * 1999-02-24 2002-05-16 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto and analogues thereof
US6291684B1 (en) 1999-03-29 2001-09-18 Bristol-Myers Squibb Company Process for the preparation of aziridinyl epothilones from oxiranyl epothilones
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
WO2000062778A1 (en) 1999-04-15 2000-10-26 Bristol-Myers Squibb Co. Cyclic protein tyrosine kinase inhibitors
AU772750C (en) * 1999-04-30 2005-02-24 Schering Aktiengesellschaft 6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations
PE20010116A1 (en) * 1999-04-30 2001-02-15 Schering Ag 6-ALKENYL-, 6-ALKINYL- AND 6-EPOXY-EPOTILONE DERIVATIVES, PROCEDURES FOR THEIR PREPARATION
AU775373B2 (en) 1999-10-01 2004-07-29 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US6518421B1 (en) * 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
US6593115B2 (en) 2000-03-24 2003-07-15 Bristol-Myers Squibb Co. Preparation of epothilone intermediates
US6589968B2 (en) * 2001-02-13 2003-07-08 Kosan Biosciences, Inc. Epothilone compounds and methods for making and using the same
UA75365C2 (en) * 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
EP1938821B1 (en) 2001-01-25 2016-03-30 Bristol-Myers Squibb Company Dosage forms of an epothilone analogue for the treatment of cancer
HUP0302567A2 (en) 2001-01-25 2003-12-29 Bristol-Myers Squibb Co. Parenteral formulation containing epothilone analogs and process for their preparation
NZ526871A (en) 2001-01-25 2006-01-27 Bristol Myers Squibb Co Pharmaceutical dosage forms of epothilones for oral administration
US6893859B2 (en) * 2001-02-13 2005-05-17 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
WO2002066033A1 (en) 2001-02-20 2002-08-29 Bristol-Myers Squibb Company Epothilone derivatives for the treatment of refractory tumors
WO2002066038A1 (en) 2001-02-20 2002-08-29 Bristol-Myers Squibb Company Treatment of refractory tumors using epothilone derivatives
NZ527557A (en) * 2001-02-27 2005-05-27 Biotechnolog Forschung Gmbh Degradation of epothilones and ethynyl substituted epothilones
ES2384789T3 (en) 2001-03-14 2012-07-12 Bristol-Myers Squibb Company Combination of an analogue of epothilone and chemotherapeutic agents for the treatment of proliferative diseases
JP2004532888A (en) 2001-06-01 2004-10-28 ブリストル−マイヤーズ　スクイブ　カンパニー Epothilone derivative
TW200303202A (en) 2002-02-15 2003-09-01 Bristol Myers Squibb Co Method of preparation of 21-amino epothilone derivatives
AU2003218107A1 (en) 2002-03-12 2003-09-29 Bristol-Myers Squibb Company C12-cyano epothilone derivatives
ATE452896T1 (en) 2002-03-12 2010-01-15 Bristol Myers Squibb Co C3-CYANOEPOTHILONE DERIVATIVES
TW200403994A (en) 2002-04-04 2004-03-16 Bristol Myers Squibb Co Oral administration of EPOTHILONES
TW200400191A (en) 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
US7405234B2 (en) 2002-05-17 2008-07-29 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
AU2003243561A1 (en) 2002-06-14 2003-12-31 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
CN1759115A (en) 2002-08-23 2006-04-12 索隆-基特林癌症研究协会 Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
KR101406635B1 (en) 2002-09-23 2014-06-11 브리스톨-마이어스 스큅 컴퍼니 Methods for the preparation, isolation and purification of epothilone b, and x-ray crystal structures of epothilone b
AU2003302084A1 (en) 2002-11-15 2004-06-15 Bristol-Myers Squibb Company Open chain prolyl urea-related modulators of androgen receptor function
US7820702B2 (en) 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
US7378426B2 (en) 2004-03-01 2008-05-27 Bristol-Myers Squibb Company Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
US7625923B2 (en) 2004-03-04 2009-12-01 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
US7696241B2 (en) 2004-03-04 2010-04-13 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
PE20061058A1 (en) * 2004-11-18 2006-10-13 Bristol Myers Squibb Co PHARMACEUTICAL COMPOSITION INCLUDING IXABEPILONE AND PREPARATION PROCESS
EP1824458A1 (en) * 2004-11-18 2007-08-29 Bristol-Myers Squibb Company Enteric coated bead comprising epothilone or an epothilone analog, and preparation and administration thereof
JP4954983B2 (en) 2005-05-18 2012-06-20 ファーマサイエンス・インコーポレイテッド BIR domain binding compound
EP2024362A4 (en) 2006-05-16 2012-01-25 Pharmascience Inc Iap bir domain binding compounds
EP2089411A4 (en) 2006-12-04 2010-01-27 Univ Illinois Compositions and methods to treat cancer with cupredoxins and cpg rich dna
US9284350B2 (en) 2010-02-12 2016-03-15 Pharmascience Inc. IAP BIR domain binding compounds
EP2665493B1 (en) 2011-01-20 2018-03-21 Board Of Regents, The University Of Texas System Mri markers, delivery and extraction systems, and methods of manufacture and use thereof
MX368966B (en) 2011-06-10 2019-10-23 Mersana Therapeutics Inc Protein-polymer-drug conjugates.
CN102863474A (en) 2011-07-09 2013-01-09 陈小平 Platinum compounds for treating cell proliferative diseases and preparation method and application thereof
CN102993239A (en) 2011-09-19 2013-03-27 陈小平 Platinum compound of succinic acid derivative with leaving group containing amino or alkylamino
EP2924044B1 (en) 2012-11-17 2018-10-31 Beijing Shuobai Pharmaceutical Co., LTD Platinum compound of malonic acid derivative having leaving group containing amino or alkylamino
CA2892863C (en) 2012-12-10 2022-03-15 Mersana Therapeutics, Inc. Polymeric scaffold based on phf for targeted drug delivery
US9872918B2 (en) 2012-12-12 2018-01-23 Mersana Therapeutics, Inc. Hydroxyl-polymer-drug-protein conjugates
TN2015000543A1 (en) 2013-06-11 2017-04-06 Bayer Pharma AG Combinations for the treatment of cancer comprising a mps-1 kinase inhibitor and a mitotic inhibitor
EP3054991B1 (en) 2013-10-11 2019-04-03 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
JP6427564B2 (en) 2013-10-11 2018-11-21 アサナ・バイオサイエンシズ，リミテッド・ライアビリティ・カンパニー Protein-polymer-drug conjugate
EP3474901A1 (en) 2016-06-27 2019-05-01 Tagworks Pharmaceuticals B.V. Cleavable tetrazine used in bio-orthogonal drug activation
US11135307B2 (en) 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
EP3641826B1 (en) 2017-06-22 2023-12-06 Mersana Therapeutics, Inc. Methods of producing drug-carrying polymer scaffolds and protein-polymer-drug conjugates
WO2019212356A1 (en) 2018-05-04 2019-11-07 Tagworks Pharmaceuticals B .V. Tetrazines for high click conjugation yield in vivo and high click release yield
US20210308207A1 (en) 2018-05-04 2021-10-07 Tagworks Pharmaceuticals B.V. Compounds comprising a linker for increasing transcyclooctene stability
EA202191175A1 (en) 2018-10-29 2021-09-08 Мерсана Терапьютикс, Инк. CYSTEINE-DESIGNED ANTIBODY-DRUG CONJUGATES CONTAINING PEPTIDE-CONTAINING LINKERS
US20230121556A1 (en) 2019-06-17 2023-04-20 Tagworks Pharmaceuticals B.V. Compounds for fast and efficient click release
IL289094A (en) 2019-06-17 2022-02-01 Tagworks Pharmaceuticals B V Tetrazines for high click release speed and yield
CA3230774A1 (en) 2021-09-06 2023-03-09 Veraxa Biotech Gmbh Novel aminoacyl-trna synthetase variants for genetic code expansion in eukaryotes
CA3238627A1 (en) 2021-11-25 2023-06-01 Christine Kohler Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion
EP4186529A1 (en) 2021-11-25 2023-05-31 Veraxa Biotech GmbH Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion
WO2023104941A1 (en) 2021-12-08 2023-06-15 European Molecular Biology Laboratory Hydrophilic tetrazine-functionalized payloads for preparation of targeting conjugates
WO2023158305A1 (en) 2022-02-15 2023-08-24 Tagworks Pharmaceuticals B.V. Masked il12 protein
WO2024013723A1 (en) 2022-07-15 2024-01-18 Pheon Therapeutics Ltd Antibody drug conjugates that bind cdcp1 and uses thereof
WO2024080872A1 (en) 2022-10-12 2024-04-18 Tagworks Pharmaceuticals B.V. Strained bicyclononenes

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993010121A1 (en) * 1991-11-19 1993-05-27 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Epothilones, process for preparing the same and their use as medicaments and as plant protecting agents

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59609305D1 (en) * 1995-11-17 2002-07-11 Biotechnolog Forschung Gmbh Epothilone derivatives and their production
US6441186B1 (en) * 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
EP1201666A3 (en) * 1997-02-25 2003-03-05 Gesellschaft für biotechnologische Forschung mbH (GBF) Epothilones with a modified side chain

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993010121A1 (en) * 1991-11-19 1993-05-27 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Epothilones, process for preparing the same and their use as medicaments and as plant protecting agents

Also Published As

Publication number Publication date
KR100494179B1 (en) 2005-06-10
ZA981575B (en) 1998-09-08
EP0975638B1 (en) 2002-08-07
IL131343A (en) 2004-03-28
NO327211B1 (en) 2009-05-11
NZ337195A (en) 2001-05-25
TW480263B (en) 2002-03-21
DE19880193D2 (en) 2000-08-24
CN1544436A (en) 2004-11-10
AU736062B2 (en) 2001-07-26
PL190422B1 (en) 2005-12-30
EP1201666A3 (en) 2003-03-05
HUP0002189A2 (en) 2001-10-28
RU2201932C2 (en) 2003-04-10
KR20000075705A (en) 2000-12-26
PT975638E (en) 2002-12-31
ATE221888T1 (en) 2002-08-15
CN1248974A (en) 2000-03-29
HK1023774A1 (en) 2000-09-22
AR011878A1 (en) 2000-09-13
NO994071D0 (en) 1999-08-24
US6359140B1 (en) 2002-03-19
HU228851B1 (en) 2013-06-28
HUP0002189A3 (en) 2001-12-28
DE59805110D1 (en) 2002-09-12
DK0975638T3 (en) 2002-11-18
IL131343A0 (en) 2001-01-28
BR9807742A (en) 2000-02-22
WO1998038192A1 (en) 1998-09-03
CA2281105A1 (en) 1998-09-03
CN1128803C (en) 2003-11-26
NO994071L (en) 1999-10-21
AU6724998A (en) 1998-09-18
EP0975638A1 (en) 2000-02-02
BR9807742B1 (en) 2010-12-14
PL335329A1 (en) 2000-04-25
ES2183338T3 (en) 2003-03-16
JP2001513098A (en) 2001-08-28
EP1201666A2 (en) 2002-05-02
CZ286599A3 (en) 2000-03-15

Similar Documents

Publication Publication Date Title
CZ298027B6 (en) Process for preparing epothilone-N-oxides and N-oxides of epothilones per se
Moore et al. Fontonamide and anhydrohapaloxindole A, two new alkaloids from the blue-green alga Hapalosiphon fontinalis
AU705245B2 (en) Sesquiterpene derivatives having antiviral activity
KR910008799B1 (en) Epipodophyllotokin glucoside 4-acyl derivatives
CN1082509C (en) Camptothecin-skeleton compounds isolated from mappia foetida and use thereof as syntones for medicaments as well as therapeutical agents
Kohout et al. Brassino steroids with androstane and pregnane skeleton
WO2022197182A1 (en) Methods for preparing cyclooctenes and conjugates thereof
US5876984A (en) Sequiterpene derivatives having antiviral activity
Tapolcsányi et al. The Mitsunobu inversion reaction of sterically hindered 17-hydroxy steroids
CS200538B2 (en) Method of producing derivatives of oleandomycin
JPH0121146B2 (en)
KR100500498B1 (en) Sulfur Oxidation of Estrogen Mixtures
PL182354B1 (en) Equilin isomerising process
Ishii et al. Studies on lysergic acid diethylamide and related compounds. Part 8. Structural identification of new metabolites of lysergic acid diethylamide obtained by microbial transformation using Streptomyces roseochromogenes
Burnett et al. An improved synthesis for 2β-hydroxytestosterone
EP0987268B1 (en) Pharmaceutical agents containing epothilone A-N-oxide and/or epothilone B-N-oxide
Uoto et al. Preparation of large macrocyclic tetra‐amines consisting of a methylene backbone and a cyclophane type skeleton
Chéry et al. Vinyl bis-sulfone methodology in thiosugars: selective access to chiral thiovinyl sulfones and PSE oxathianes
KR790001979B1 (en) Process for the preparation of cyclopentane derivatives
Paulik et al. Semisynthetic analogues of Buxus alkaloids
ES2448217T3 (en) Polyketide molecules as anticancer agents
KR840000864B1 (en) Process for preparing analogs of prostacyclin
MXPA99007546A (en) Epothilones with a modified side chain
Wittmann et al. Supplemental Data Structures of the Human Orotidine-5′-Monophosphate Decarboxylase Support a Covalent Mechanism and Provide a Framework for Drug Design
PL148349B2 (en) The method of manufacture of derivatives of 3-hydroxymethyl-4-alcoxy-azetidinone

Legal Events

Date Code Title Description
PD00 Pending as of 2000-06-30 in czech republic
MK4A Patent expired

Effective date: 20180225